Extracorporeal liver support therapy with Prometheus in patients with hepato-renal syndrome

Extracorporeal liver support therapy with Prometheus in patients with hepato-renal syndrome - LUTHER pilot study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00000441

Enrollment

Registered

2010-06-08

Start date

2010-06-05

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K76.7

Interventions

Group 1: standard medical therapy (vasopressors: Terlipressin 4x1-2 mg/day or Noradrenalin

human serum albumin 20-40 g/die) Group 2: standard medical therapy plus 5-8 treatments with Prometheus FPSA (up to daily FPSA treatment on day 1-8, 4-6 hours each)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: hepato-renal syndrome; informed consent (by patient or legal representative); absence of exclusion criteria

Exclusion criteria

Exclusion criteria: acive bleeding complications; severe thrombocytopenia (platelets < 20,000/µl); participation in other study within the last 3 months.

Design outcomes

Primary

Measure	Time frame
Kidney function (glomerular filtration rate, GFR) on day 15 of study	—

Secondary

Measure	Time frame
renal replacement therapy; urine volume; body weight; urinary sodium output; serum sodium concentration; MELD Score; degree of encephalopathy	—

Countries

Germany

Contacts

Public ContactAchim Jörres

Charité-Universitätsmedizin Berlin Med. Klinik m.S. Nephrologie und internistische Intensivmedizin

achim.joerres@charite.de+49 30 450 553 423

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026